CD4 and neoplasm: SC134-TCB led to a 64% tumor growth inhibition, P = 0.0249 (Fig. 4F), concomitant with a significantly increased CD4+ as well as CD8+ T-cell content (Fig. 4E; Supplementary Fig. S9D).